세계의 당화 알부민 분석 시장 : 용도별(경계형 당뇨병, 1형 당뇨병, 2형 당뇨병), 최종사용자별(병원 및 당뇨병 치료 센터, 진단 검사실), 지역별(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카) 예측(-2028년)

Glycated Albumin Assay Market by Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User (Hospitals & Diabetic Care Center, Diagnostic Laboratory) & Region (North America, Europe, APAC, Latin America, & MENA) - Global Forecast to 2028

US $ 4,950 ￦ 6,907,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,279,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,372,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,954,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 당화 알부민 분석 시장 규모는 2023년 2억 달러에서 2028년 3억 달러에 달할 것으로 예상되며, 예측 기간 동안 8.9%의 CAGR을 기록할 것으로 예상됩니다.

시장 성장의 원동력은 65세 이상 당뇨병 환자의 증가와 질병 진단에 대한 정부의 노력과 같은 요인입니다. 반면, 불리한 상환 시나리오와 같은 문제는 시장 성장의 주요 억제요인으로 작용하고 있습니다.

"경계형 당뇨병이 예측 기간 동안 용도별 성장률이 가장 높을 것으로 예상"

용도별로 당화 알부민 분석 시장을 살펴보면, 경계성 당뇨병이 2022년까지 가장 높은 시장 성장률을 보였습니다. 당뇨병과 같은 생활습관병 예방에 대한 관심 증가, 진단 검사실 증가, 신흥국의 의료 인프라 개선이 이 부문의 성장에 기여하는 주요 요인입니다.

"최종사용자별로는 진단 실험실 분야가 예측 기간 동안 가장 높은 성장률을 기록할 것"

최종사용자별로 당화 알부민 분석 시장을 살펴보면, 진단 실험실 부문이 2022년까지 가장 높은 성장률을 보였습니다. 진단 실험실은 의료 서비스 제공자와 환자에게 비용 효율적이고 편리한 검사 옵션을 제공합니다. 진단 검사실에 당화 알부민 검사를 위탁함으로써 의료 서비스 제공자는 내부 검사 시설 및 관련 비용을 피할 수 있습니다. 또한, 환자는 입원이나 전문 병원을 방문하지 않고도 당화 알부민 검사를 위해 진단 연구소를 방문할 수 있습니다. 비용 효율성과 편의성으로 인해 진단 실험실은 매력적인 선택이며, 이는 수요 증가와 부문의 성장으로 이어질 것입니다.

"아시아태평양: 당화 알부민 분석 시장에서 가장 빠른 성장세를 보이는 지역"

세계 당화 알부민 분석 시장을 지역별로 살펴보면, 아시아태평양이 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상됩니다. 이 지역의 당화 알부민 분석 시장은 당뇨병 인식 제고 프로그램의 증가와 정부의 의료 정책의 긍정적인 영향을 받아 성장하고 있습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

제5장 시장 개요

• 서론
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 가격 분석
• 특허 분석
• 밸류체인 분석
• 공급망 분석
• 생태계 분석
• Porter's Five Forces 분석
• 규제 상황
• 무역 분석
• 기술 분석
• 주요 회의와 이벤트
• PESTLE 분석
• 고객의 비지니스에 영향을 미치는 동향/혼란
• 주요 이해관계자와 구입 기준
• 사례 연구 분석

제6장 당화 알부민 분석 시장 : 용도별

• 서론
• 2형 당뇨병
• 경계형 당뇨병
• 1형 당뇨병

제7장 당화 알부민 분석 시장 : 최종사용자별

• 서론
• 병원·당뇨병 치료 센터
• 진단 검사실
• 기타 최종사용자

제8장 당화 알부민 분석 시장 : 지역별

• 서론
• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 기타 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제9장 경쟁 상황

• 개요
• 주요 기업 매출 점유율 분석
• 시장 점유율 분석
• 당화 알부민 분석 시장 : 기업 평가 매트릭스
• 당화 알부민 분석 시장 : 스타트업/중소기업의 기업 평가 매트릭스(2022년)
• 경쟁 벤치마킹

제10장 기업 개요

• 주요 기업
  • ASAHI KASEI CORPORATION
  • BEIJING STRONG BIOTECHNOLOGIES, INC.
  • DIAZYME LABORATORIES, INC.
  • DXGEN CORP.
  • WELDON BIOTECH, INC.
  • HZYMES BIOTECH

제11장 부록

ksm

영문 목차

영문목차

The global glycated albumin assay market is projected to reach USD 0.3 billion by 2028 from USD 0.2 billion in 2023, at a CAGR of 8.9% during the forecast period. Market growth is driven by factors such as the increased number of diabetic patients above the age of 65 years and government initiatives for disease diagnosis. On the other hand, challenges associated with the glycated albumin assay market, like unfavorable reimbursement scenarios, are the major factors restricting market growth.

"The prediabetic segment accounted for the highest growth rate in the glycated albumin assay market, by application, during the forecast period"

The glycated albumin assay market is segmented into prediabetes, type 1 diabetes, and type 2 diabetes. In 2022, the prediabetes segment accounted for the highest glycated albumin assay market growth rate. The increasing focus on the prevention of lifestyle diseases like diabetes, growth in the number of diagnostic laboratories, and improving healthcare infrastructure in emerging countries are major factors contributing to this segment's growth.

"The diagnostic laboratories segment accounted for the highest growth in the glycated albumin assay market, by end-user, during the forecast period"

The glycated albumin assay market is segmented into hospitals and diabetes care centers, diagnostic laboratories, and other end-user based on end users. In 2022, the diagnostic laboratories segment accounted for the highest glycated albumin assay market growth rate. Diagnostics laboratories often offer cost-effective and convenient testing options for healthcare providers and patients. By outsourcing glycated albumin testing to diagnostics laboratories, healthcare providers can avoid the need for in-house testing facilities and associated costs. Additionally, patients can visit diagnostics laboratories for their glycated albumin assays without the need for hospitalization or specialized clinic visits. The cost-effectiveness and convenience of diagnostics laboratories make them an attractive option, leading to increased demand and segment growth.

"Asia Pacific: The fastest-growing region in glycated albumin assay market"

The North American, European, Asia Pacific, Latin American, Middle Eastern, and African regions make up the major segments of the worldwide glycated albumin assay market. The highest CAGR is anticipated to be recorded over the forecast period in the Asia Pacific region. The glycated albumin assay market in this region is expanding as a result of an increase in diabetes awareness programmes and favourable government healthcare policies.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6% , and the Middle East & Africa - 4%

List of Companies Profiled in the Report:

• Asahi Kasei Corporation (Japan)
• Beijing Strong Biotechnologies, Inc. (China)
• Diazyme Laboratories, Inc. (US)
• DxGen Corp. (South Korea)
• Weldon Biotech, Inc.(India)
• Hzymes Biotech (China)

Research Coverage:

This report provides a detailed picture of the global glycated albumin assay market. It aims at estimating the size and future growth potential of the market across different segments, such as application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profile and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall glycated albumin assay market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKET SEGMENTATION
  • 1.3.2 GEOGRAPHICAL SCOPE
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • FIGURE 1 GLYCATED ALBUMIN ASSAY MARKET: RESEARCH DESIGN METHODOLOGY
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
  • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
    • 2.3.1.2 Approach 2: Primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 Glycated Albumin Assay Market: CAGR Projections
  • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • 2.3.2 TOP-DOWN APPROACH
  • FIGURE 6 GLYCATED ALBUMIN ASSAY MARKET: TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION METHODOLOGY
  • FIGURE 7 DATA TRIANGULATION METHODOLOGY
• 2.5 MARKET SHARE ANALYSIS
• 2.6 STUDY ASSUMPTIONS
• 2.7 STUDY LIMITATIONS
• 2.8 GROWTH RATE ASSUMPTIONS
• 2.9 RISK ASSESSMENT
  • 2.9.1 GLYCATED ALBUMIN ASSAY MARKET: RISK ASSESSMENT ANALYSIS
• 2.10 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

• FIGURE 8 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
• FIGURE 9 GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
• FIGURE 10 GLYCATED ALBUMIN ASSAY MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

• 4.1 GLYCATED ALBUMIN ASSAY MARKET OVERVIEW
  • FIGURE 11 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET
• 4.2 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2023 VS. 2028
  • FIGURE 12 TYPE 2 DIABETES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• 4.3 GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2023 VS. 2028
  • FIGURE 13 HOSPITALS AND DIABETIC CARE CENTERS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• 4.4 GLYCATED ALBUMIN ASSAY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
  • FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 15 GLYCATED ALBUMIN ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising incidence of diabetes
  • FIGURE 16 PREVALENCE OF DIABETES IN ADULTS (20-79 YEARS), BY REGION, 2021 VS. 2045 (USD MILLION)
  • TABLE 1 TOTAL HEALTH EXPENDITURE (USD) FOR DIABETES (20-79 YEARS), BY COUNTRY (2021)
    • 5.2.1.2 Growing focus on early detection of diabetes
    • 5.2.1.3 Increase in age-associated diabetic ailments
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Unfavorable reimbursement scenario
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising investments in life sciences research
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory requirements for diagnostic products
    • 5.2.4.2 Presence of alternative tests
• 5.3 PRICING ANALYSIS
  • TABLE 2 AVERAGE SELLING PRICE OF GLYCATED ALBUMIN ASSAY PRODUCTS
• 5.4 PATENT ANALYSIS
  • FIGURE 17 PATENT ANALYSIS FOR GLYCATED ALBUMIN ASSAYS (JANUARY 2013-DECEMBER 2022)
  • 5.4.1 GLYCATED ALBUMIN ASSAY MARKET: LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
  • FIGURE 18 GLYCATED ALBUMIN ASSAY MARKET: MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASES
• 5.6 SUPPLY CHAIN ANALYSIS
  • FIGURE 19 GLYCATED ALBUMIN ASSAY MARKET: SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • FIGURE 20 GLYCATED ALBUMIN ASSAY MARKET: ECOSYSTEM MAP
  • 5.7.1 GLYCATED ALBUMIN ASSAY MARKET: ECOSYSTEM ROLE
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 3 GLYCATED ALBUMIN ASSAY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 THREAT OF NEW ENTRANTS
  • 5.8.2 THREAT OF SUBSTITUTES
  • 5.8.3 BARGAINING POWER OF BUYERS
  • 5.8.4 BARGAINING POWER OF SUPPLIERS
  • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.9 REGULATORY LANDSCAPE
  • TABLE 4 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 6 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 MIDDLE EAST: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9.1 NORTH AMERICA
    • 5.9.1.1 US
    • 5.9.1.2 Canada
  • 5.9.2 EUROPE
  • TABLE 8 EUROPE: CLASSIFICATION OF DEVICES
  • 5.9.3 ASIA PACIFIC
    • 5.9.3.1 China
    • 5.9.3.2 Japan
    • 5.9.3.3 India
  • 5.9.4 LATIN AMERICA
    • 5.9.4.1 Brazil
    • 5.9.4.2 Mexico
  • 5.9.5 MIDDLE EAST
  • 5.9.6 AFRICA
• 5.10 TRADE ANALYSIS
  • 5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
    • 5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
    • 5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
• 5.11 TECHNOLOGY ANALYSIS
• 5.12 KEY CONFERENCES AND EVENTS
  • TABLE 9 DETAILED LIST OF CONFERENCES AND EVENTS (2022-2023)
• 5.13 PESTLE ANALYSIS
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 21 GLYCATED ALBUMIN ASSAY MARKET: REVENUE SHIFT MAPPING
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR GLYCATED ALBUMIN ASSAYS
  • TABLE 10 GLYCATED ALBUMIN ASSAY MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
  • 5.15.2 BUYING CRITERIA
  • FIGURE 23 GLYCATED ALBUMIN ASSAY MARKET: KEY BUYING CRITERIA
  • TABLE 11 KEY BUYING CRITERIA FOR GLYCATED ALBUMIN ASSAYS, BY END USER
• 5.16 CASE STUDY ANALYSIS
  • FIGURE 24 CASE STUDY ANALYSIS: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA

6 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION

• 6.1 INTRODUCTION
  • TABLE 12 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• 6.2 TYPE 2 DIABETES
  • 6.2.1 DIETARY AND LIFESTYLE CHANGES TO CONTRIBUTE TO MARKET GROWTH
  • TABLE 13 GLYCATED ALBUMIN ASSAY MARKET FOR TYPE 2 DIABETES, BY REGION, 2021-2028 (USD MILLION)
• 6.3 PREDIABETES
  • 6.3.1 INSULIN RESISTANCE AND RISING CASES OF PREDIABETES TO DRIVE MARKET
  • TABLE 14 GLYCATED ALBUMIN ASSAY MARKET FOR PREDIABETES, BY REGION, 2021-2028 (USD MILLION)
• 6.4 TYPE 1 DIABETES
  • 6.4.1 INCREASING INCIDENCE AMONG CHILDREN AND ADOLESCENTS TO SUPPORT MARKET GROWTH
  • TABLE 15 INCIDENCE OF TYPE 1 DIABETES IN CHILDREN AND ADOLESCENTS AGED 0 TO 19, BY REGION, 2021 (THOUSANDS)
  • TABLE 16 GLYCATED ALBUMIN ASSAY MARKET FOR TYPE 1 DIABETES, BY REGION, 2021-2028 (USD MILLION)

7 GLYCATED ALBUMIN ASSAY MARKET, BY END USER

• 7.1 INTRODUCTION
  • TABLE 17 GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
• 7.2 HOSPITALS AND DIABETES CARE CENTERS
  • 7.2.1 ABILITY TO OFFER RAPID RESULTS IN ACCESSIBLE SETTING TO DRIVE MARKET
  • TABLE 18 GLYCATED ALBUMIN ASSAY MARKET FOR HOSPITALS AND DIABETES CARE CENTERS, BY REGION, 2021-2028 (USD MILLION)
• 7.3 DIAGNOSTIC LABORATORIES
  • 7.3.1 RISING OUTSOURCING OF RESEARCH ACTIVITIES FOR COST REDUCTION TO DRIVE MARKET
  • TABLE 19 GLYCATED ALBUMIN ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
• 7.4 OTHER END USERS
  • TABLE 20 GLYCATED ALBUMIN ASSAY MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

8 GLYCATED ALBUMIN ASSAY MARKET, BY REGION

• 8.1 INTRODUCTION
  • TABLE 21 GLYCATED ALBUMIN ASSAY MARKET, BY REGION, 2021-2028 (USD MILLION)
• 8.2 NORTH AMERICA
  • FIGURE 25 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET SNAPSHOT
  • TABLE 22 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 23 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 24 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.2.1 US
    • 8.2.1.1 High healthcare expenditure for diabetes treatment & diagnosis to drive market
  • TABLE 25 US: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 26 US: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.2.2 CANADA
    • 8.2.2.1 Rising awareness of early diabetes detection to support market growth
  • TABLE 27 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029
  • TABLE 28 CANADA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 29 CANADA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.2.3 NORTH AMERICA: RECESSION IMPACT
• 8.3 EUROPE
  • TABLE 30 PREVALENCE OF DIABETES IN EUROPE, 2021 VS. 2045
  • TABLE 31 EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 32 EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 33 EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.3.1 GERMANY
    • 8.3.1.1 Provision of healthcare coverage for technologically advanced assays to drive market
  • TABLE 34 GERMANY: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 35 GERMANY: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.3.2 UK
    • 8.3.2.1 Rising geriatric population and diabetes-associated ailments to drive market
  • TABLE 36 UK: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 37 UK: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.3.3 FRANCE
    • 8.3.3.1 Increasing R&D expenditure for product commercialization to drive market
  • TABLE 38 FRANCE: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 39 FRANCE: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.3.4 ITALY
    • 8.3.4.1 Improvements in healthcare infrastructure to support market growth
  • TABLE 40 ITALY: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 41 ITALY: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.3.5 SPAIN
    • 8.3.5.1 Rising incidence of diabetes among senior women to support market growth
  • TABLE 42 SPAIN: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 43 SPAIN: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.3.6 REST OF EUROPE
  • TABLE 44 REST OF EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 45 REST OF EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.3.7 EUROPE: RECESSION IMPACT
• 8.4 ASIA PACIFIC
  • FIGURE 26 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET SNAPSHOT
  • TABLE 46 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 48 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.4.1 CHINA
    • 8.4.1.1 Improving healthcare infrastructure to propel market
  • TABLE 49 CHINA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 50 CHINA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.4.2 JAPAN
    • 8.4.2.1 Universal healthcare reimbursement policy to support market growth
  • TABLE 51 JAPAN: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 52 JAPAN: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.4.3 INDIA
    • 8.4.3.1 implementation of favorable government initiatives to drive market
  • TABLE 53 INDIA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 54 INDIA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.4.4 REST OF ASIA PACIFIC
  • TABLE 55 REST OF ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 56 REST OF ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.4.5 ASIA PACIFIC: RECESSION IMPACT
• 8.5 LATIN AMERICA
  • 8.5.1 RISING GOVERNMENT-FUNDED PROGRAMS FOR ACCURATE AND EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
  • TABLE 57 LATIN AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 58 LATIN AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.5.2 LATIN AMERICA: RECESSION IMPACT
• 8.6 MIDDLE EAST & AFRICA
  • 8.6.1 EXPANSION OF KEY MARKET PLAYERS TO SUPPORT MARKET GROWTH
  • TABLE 59 MIDDLE EAST & AFRICA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 60 MIDDLE EAST & AFRICA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS
  • FIGURE 27 GLYCATED ALBUMIN ASSAY MARKET: REVENUE SHARE ANALYSIS
• 9.3 MARKET SHARE ANALYSIS
  • 9.3.1 GLYCATED ALBUMIN ASSAY MARKET
  • FIGURE 28 GLYCATED ALBUMIN ASSAY MARKET SHARE, BY KEY PLAYER (2022)
  • TABLE 61 GLYCATED ALBUMIN ASSAY MARKET: INTENSITY OF COMPETITIVE RIVALRY
• 9.4 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX
  • 9.4.1 STARS
  • 9.4.2 EMERGING LEADERS
  • 9.4.3 PERVASIVE PLAYERS
  • 9.4.4 PARTICIPANTS
  • FIGURE 29 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX (2022)
• 9.5 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
  • 9.5.1 PROGRESSIVE COMPANIES
  • 9.5.2 STARTING BLOCKS
  • 9.5.3 RESPONSIVE COMPANIES
  • 9.5.4 DYNAMIC COMPANIES
  • FIGURE 30 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
• 9.6 COMPETITIVE BENCHMARKING
  • 9.6.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
  • FIGURE 31 GLYCATED ALBUMIN ASSAY MARKET: PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
  • TABLE 62 GLYCATED ALBUMIN ASSAY MARKET: COMPETITIVE EVALUATION OF KEY PLAYERS
  • TABLE 63 GLYCATED ALBUMIN ASSAY MARKET: COMPANY PRODUCT FOOTPRINT
  • TABLE 64 GLYCATED ALBUMIN ASSAY MARKET: COMPANY REGIONAL FOOTPRINT

10 COMPANY PROFILES

• (Business overview, Products offered, Recent Developments, MNM view)**
• 10.1 KEY PLAYERS
  • 10.1.1 ASAHI KASEI CORPORATION
  • TABLE 65 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
  • FIGURE 32 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022)
  • 10.1.2 BEIJING STRONG BIOTECHNOLOGIES, INC.
  • TABLE 66 BEIJING STRONG BIOTECHNOLOGIES, INC.: BUSINESS OVERVIEW
  • FIGURE 33 BEIJING STRONG BIOTECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
  • 10.1.3 DIAZYME LABORATORIES, INC.
  • TABLE 67 DIAZYME LABORATORIES, INC.: COMPANY OVERVIEW
  • 10.1.4 DXGEN CORP.
  • TABLE 68 DXGEN CORP: COMPANY OVERVIEW
  • 10.1.5 WELDON BIOTECH, INC.
  • TABLE 69 WELDON BIOTECH, INC.: COMPANY OVERVIEW
  • 10.1.6 HZYMES BIOTECH
  • TABLE 70 HZYMES BIOTECH: COMPANY OVERVIEW
• *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

11 APPENDIX

• 11.1 DISCUSSION GUIDE
• 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 11.3 CUSTOMIZATION OPTIONS
• 11.4 RELATED REPORTS
• 11.5 AUTHOR DETAILS

관련자료